BDBM107700 US11426393, Compound Table XV.6::US8598210, Table XV, 6::US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyridine-2- carbonyl)-amino]-acetic acid methyl ester::US9598370, Example 00131::USRE47437, Example [(3-Hydroxy-5-(4-methylphenyl)-pyridine-2-carbonyl)-amino]-acetic acid methyl ester

SMILES COC(=O)CNC(=O)c1ncc(cc1O)-c1ccc(C)cc1

InChI Key InChIKey=DSAKFJKYBXTHSR-UHFFFAOYSA-N

Data  10 IC50  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 107700   

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 4.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 5.23E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataEC50:  8.20E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 4.10E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 5.23E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 4.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 5.23E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataEC50:  8.20E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 4.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 5.23E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataEC50:  8.20E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 4.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 5.23E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataEC50:  8.20E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 ceils per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent